DYNC1LI2: A Promising Drug Target / Biomarker (G1783)

Target Name: DYNC1LI2

NCBI ID: G1783

DYNC1LI2

DYNC1LI2: A Promising Drug Target / Biomarker

Drug resistance is a major issue in modern medicine, and the development of new drugs to treat resistant bacterial and viral infections is a continuous process. One of the growing areas of research in this field is the identification of new targets for anti-infective drugs. One such target is DYNC1LI2, a protein that is expressed in many different tissues and cell types, including the respiratory tract and the urinary tract. In this article, we will explore the potential of DYNC1LI2 as a drug target and discuss its potential as a biomarker for the diagnosis and treatment of various diseases.

The Protein DYNC1LI2

DYNC1LI2 is a protein that is expressed in many different tissues and cell types, including the respiratory tract, the gut, and the urinary tract. It is a member of the DYSCON Family, which includes several other proteins that are involved in cell signaling and transport. The DYSCON Family is a growing area of research, and there is increasing interest in the functions of these proteins in various physiological processes.

One of the key functions of DYNC1LI2 is its role in cell signaling. DYNC1LI2 is involved in the regulation of T cell responses, and it has been shown to play a role in the development of cancer. In addition, DYNC1LI2 is also involved in the regulation of immune cell responses, as well as in the regulation of inflammation and pain.

DYNC1LI2 is also of interest as a potential drug target because of its expression in a wide range of tissues and cell types. This makes it an attractive target for the development of new anti-infective drugs, as it is likely to be expressed in many different tissues that are affected by bacterial and viral infections. In addition, DYNC1LI2 is also expressed in the respiratory tract and urinary tract, which are sites of frequent bacterial and viral infections.

Potential Applications of DYNC1LI2 as a Drug Target

The identification of DYNC1LI2 as a potential drug target has significant implications for the development of new anti-infective drugs. One of the key advantages of DYNC1LI2 as a drug target is its widespread expression in different tissues and cell types. This makes it an attractive target for the development of drugs that can affect a wide range of bacterial and viral infections.

In addition, DYNC1LI2 is involved in the regulation of many different cellular processes, which makes it an attractive target for the development of drugs that can affect a wide range of cellular functions. This makes it an attractive target for the development of drugs that can affect a wide range of cellular processes, including cell signaling, inflammation, and pain.

Another potential application of DYNC1LI2 as a drug target is its role in the development of cancer. DYNC1LI2 has been shown to play a role in the regulation of T cell responses, which are critical for the development of cancer. In addition, DYNC1LI2 has also been shown to play a role in the regulation of cancer cell growth and metastasis.

Potential Applications of DYNC1LI2 as a Biomarker

In addition to its potential as a drug target, DYNC1LI2 is also of interest as a biomarker for the diagnosis and treatment of various diseases. One of the key advantages of DYNC1LI2 as a biomarker is its widespread expression in different tissues and cell types. This makes it an attractive target for the development of biomarkers that can be used to diagnose and treat a wide range of diseases.

In addition, DYNC1LI2 is involved in the regulation of many different cellular processes, which makes it an attractive target for the development of biomarkers that can detect changes in cellular processes that are associated with the development of disease. This makes it an attractive target for the development of biomarkers that can detect the early stages of disease and help to diagnose and treat it.

Conclusion

In conclusion, DYNC1LI2 is a protein that is expressed in many different tissues and cell types, including the respiratory tract and the urinary tract. It is involved in

Protein Name: Dynein Cytoplasmic 1 Light Intermediate Chain 2

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. May play a role in binding dynein to membranous organelles or chromosomes

The "DYNC1LI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNC1LI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets